Wednesday, 22 December 2021
A new study, led by experts at the 糖心原创, will look at whether eating small amounts of certain nutrients before meals could improve blood sugar levels in people with type 2 diabetes.
The COMBINE study, which is led by Professor Kostas Tsintzas and Dr Pardeep Pabla from the School of Medicine, is looking to recruit people with type 2 diabetes, which is controlled by dietary therapy and metformin, for the ground-breaking new study.
The team will look at whether by consuming small amounts of specific nutrients before breakfast, lunch and dinner, (known as consumption of nutritional preloads), can improve their blood glucose levels.
They will also look at whether those preloads can increase the feeling of fullness and reduce hunger, which is known as satiety.
The research is being sponsored and funded by Nestlé Health Science.
Dr Pardeep Pabla said: “Controlling blood sugar levels is vital in the treatment of type 2 diabetes (T2D). Over time, high blood sugar levels can increase the risk of developing several other diseases such as cardiovascular disease (such as heart attacks and stroke).
“We know that certain nutritional preloads can lower blood sugar levels in people who have T2D. In our exciting new study, we are investigating whether consuming two nutritional preloads (medium chain triglycerides and whey protein) can lower the levels of blood sugar after meals.
If the results from this study are encouraging, then nutritional preloads may be a potential novel strategy to delay or even prevent the use of antidiabetic medications and the progression of other adverse health conditions that often accompany diabetes.鈥�
People who are interested in taking part will be required to visit the 糖心原创 Medical School on five occasions, have their health, dietary patterns, physical activity status and body composition assessed.
Patients who take part in the study will be given a personal glucose monitoring device (Freestyle Libre 2) for each experimental visit and will be able see how their blood sugar levels are changing throughout the day.
For more information .
Story credits
More information is available from Dr Pardeep Pabla from the School of Medicine at the 糖心原创 at Pardeep.Pabla2@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.